• MJHLS Brand Logo

© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Infliximab Biosimilar Maintains Remission, Trough Levels After Switch in IBD

September 03, 2026

A Japanese study found high remission and continuation rates, plus non-inferior trough levels, after patients with IBD were switched to the infliximab biosimilar CT-P13.

Biosimilar Denosumab Could Reshape Access, Costs in Osteoporosis Care: Edward Li, PharmD

September 01, 2026

Step Therapy to Biosimilars, Branded Anti-VEGF Costs More, Data Show

August 31, 2026

Natalizumab Biosimilar Shows Limited Cost-Effectiveness in MS

August 28, 2026

Nonmedical Adalimumab Biosimilar Switch Maintains Disease Control in Pediatric IBD

August 24, 2026

Featured Content

Abbreviated Biologics Pathway Could Revive Biosimilar Competition

August 19th 2026

By Sabrina McCrear

Article

An editorial modeled on Hatch-Waxman proposes an abbreviated FDA pathway granting biosimilars class-level interchangeability to spur competition.

Rituximab Biosimilars Show Comparable 6-Month Outcomes in AAV

August 14th 2026

By Brooke McCormick

Article

Rituximab biosimilars showed no significant 6-month differences vs the originator in antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Adalimumab Biosimilar Sustains Efficacy After Switch in Saudi Cohort

August 11th 2026

By Giuliana Grossi

Article

Saudi real-world study finds adalimumab biosimilar switching preserves efficacy and safety, with full response in patients with HS.

Analytical Characterization Supports Confidence in Monoclonal Antibody Biosimilars

August 6th 2026

By Brooke McCormick

Article

Analytical characterization supports monoclonal antibody biosimilar approvals and may reduce clinical testing needs, researchers found.

Biosimilar Denosumab Shows Cost-Effectiveness Over Bisphosphonates in PMO

August 4th 2026

By Skylar Jeremias

Article

Biosimilar denosumab cleared a $150,000 per QALY cost-effectiveness threshold against bisphosphonates for high-risk PMO, but not always at $100,000.

Biosimilars Round Up: July 2026

August 4th 2026

By Sabrina McCrear

Article

Congress advances biosimilar bills as new data emerge on romosozumab, tirzepatide, and ustekinumab biosimilar development.

Denosumab Biosimilar KN012 Matches Reference Drug in Phase 3 Osteoporosis Trial

July 30th 2026

By Pearl Steinzor

Article

KN012 achieved BMD equivalence with US-approved denosumab in postmenopausal women in China.

India's Anti-VEGF Biosimilars Cut Costs, Expand Access

July 30th 2026

By Brooke McCormick

Article

Anti-VEGF biosimilars in India matched reference therapy, lowered costs, and improved treatment access and adherence for retinal diseases.

Eculizumab Biosimilar Shows Durable Benefit in Long-Term aHUS

July 29th 2026

By Pearl Steinzor

Article

A 50-patient study found sustained platelet recovery and low thrombotic microangiopathy rates through 52 weeks of biosimilar therapy, with favorable safety.

Biosimilar Bills Gain Steam in Congress, But Key Reforms Still Wait

July 23rd 2026

By Skylar Jeremias

Article

Congress fast-tracks biosimilar bills to cut drug and insulin costs, while patent, rebate, and reimbursement roadblocks still stall competition.